Scientific Publications Search Search Author Impact Factor Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Janz, Martin Dr. (7) Kammertöns, Thomas Dr. (4) Kopp, Joachim Dr. (1) Leisegang, Matthias Prof. Dr. rer. nat. (2) Lusatis, Simone (1) Mathas, Stephan Dr. (9) Nguyen, Tam Hoai Dr. (1) Pezzutto, Antonio Prof. Dr. (2) Selbach, Matthias Prof. Dr. (7) Uckert, Wolfgang Prof. Dr. (3) Willimsky, Gerald Dr. (4) (-) Blankenstein, Thomas Prof. Dr. (16) (-) Daniel, Peter Prof. Dr. (1) (-) Wollert-Wulf, Brigitte (2) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) (-) 2004 (8) 2005 (10) (-) 2006 (4) 2007 (5) 2008 (5) 2009 (2) (-) 2010 (7) 2011 (5) 2012 (6) 2013 (13) 2014 (4) 2015 (5) 2016 (4) 2017 (6) 2018 (4) 2019 (6) 2021 (6) 2022 (6) 2023 (6) 2024 (2) (-) Biology of Malignant Lymphomas (3) Genetics and Genomics of Cardiovascular Diseases (1) (-) Molecular Immunology and Gene Therapy (16) Translational Oncology of Solid Tumors (1) 19 Results: Active Filter: Blankenstein, Thomas Prof. Dr.Daniel, Peter Prof. Dr.Wollert-Wulf, BrigitteBiology of Malignant LymphomasMolecular Immunology and Gene Therapy200420062010 Sort: Result score Newest to oldest Oldest to newest November 01, 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert January 01, 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein January 01, 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto August 01, 2004 / Immunity CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions L. Ohl M. Mohaupt N. Czeloth G. Hintzen Z. Kiafard J. Zwirner T. Blankenstein G. Henning R. Foerster July 01, 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein April 01, 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel February 01, 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken March 15, 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou March 01, 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel March 01, 2010 / J Mol Med Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia S. Shalapour C. Eckert K. Seeger M. Pfau J. Prada G. Henze T. Blankenstein T. Kammertoens Pagination Current page 1 Page 2 Next page Next › Last page Last »
November 01, 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
January 01, 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein
January 01, 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto
August 01, 2004 / Immunity CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions L. Ohl M. Mohaupt N. Czeloth G. Hintzen Z. Kiafard J. Zwirner T. Blankenstein G. Henning R. Foerster
July 01, 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein
April 01, 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
February 01, 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
March 15, 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
March 01, 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
March 01, 2010 / J Mol Med Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia S. Shalapour C. Eckert K. Seeger M. Pfau J. Prada G. Henze T. Blankenstein T. Kammertoens